Reshma Rangwala - Apr 29, 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP & Chief Medical Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Reshma Rangwala
Stock symbol
KPTI
Transactions as of
Apr 29, 2022
Transactions value $
$0
Form type
4
Date filed
5/2/2022, 05:01 PM
Previous filing
Apr 29, 2022
Next filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +65K $0.00 65K Apr 29, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KPTI Stock Option (right to buy) Award $0 +100K $0.00 100K Apr 29, 2022 Common Stock 100K $6.10 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Inducement Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning April 29, 2023.
F2 This option was granted on April 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on April 29, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.